Literature DB >> 15017358

Probing the pathways of chylomicron and HDL metabolism using adenovirus-mediated gene transfer.

Vassilis I Zannis1, Angeliki Chroni, Kyriakos E Kypreos, Horng-Yuan Kan, Thais Borges Cesar, Eleni E Zanni, Dimitris Kardassis.   

Abstract

PURPOSE OF THE REVIEW: This review clarifies the functions of key proteins of the chylomicron and the HDL pathways. RECENT
FINDINGS: Adenovirus-mediated gene transfer of several apolipoprotein (apo)E forms in mice showed that the amino-terminal 1-185 domain of apoE can direct receptor-mediated lipoprotein clearance in vivo. Clearance is mediated mainly by the LDL receptor. The carboxyl-terminal 261-299 domain of apoE induces hypertriglyceridemia, because of increased VLDL secretion, diminished lipolysis and inefficient VLDL clearance. Truncated apoE forms, including apoE2-202, have a dominant effect in remnant clearance and may have future therapeutic applications for the correction of remnant removal disorders. Permanent expression of apoE and apoA-I following adenoviral gene transfer protected mice from atherosclerosis. Functional assays, protein cross-linking, and adenovirus-mediated gene transfer of apoA-I mutants in apoA-I deficient mice showed that residues 220-231, as well as the central helices of apoA-I, participate in ATP-binding cassette transporter A1-mediated lipid efflux and HDL biogenesis. Following apoA-I gene transfer, an amino-terminal deletion mutant formed spherical alpha-HDL, a double amino- and carboxyl-terminal deletion mutant formed discoidal HDL, and a carboxyl-terminal deletion mutant formed only pre-beta-HDL. The findings support a model of cholesterol efflux that requires direct physical interactions between apoA-I and ATP-binding cassette transporter A1, and can explain Tangier disease and other HDL deficiencies.
SUMMARY: New insights are provided into the role of apoE in cholesterol and triglyceride homeostasis, and of apoA-I in the biogenesis of HDL. Clearance of the lipoprotein remnants and increase in HDL synthesis are obvious targets for therapeutic interventions.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15017358     DOI: 10.1097/00041433-200404000-00008

Source DB:  PubMed          Journal:  Curr Opin Lipidol        ISSN: 0957-9672            Impact factor:   4.776


  23 in total

1.  Adrenoceptor-related decrease in serum triglycerides is independent of PPARα activation.

Authors:  Maria Konstandi; Kyriakos E Kypreos; Tsutomu Matsubara; Eva Xepapadaki; Yatrik M Shah; Kristopher Krausz; Christina E Andriopoulou; Aristeidis Kofinas; Frank J Gonzalez
Journal:  FEBS J       Date:  2019-06-28       Impact factor: 5.542

2.  Pathway of biogenesis of apolipoprotein E-containing HDL in vivo with the participation of ABCA1 and LCAT.

Authors:  Kyriakos E Kypreos; Vassilis I Zannis
Journal:  Biochem J       Date:  2007-04-15       Impact factor: 3.857

3.  Biophysical analysis of progressive C-terminal truncations of human apolipoprotein E4: insights into secondary structure and unfolding properties.

Authors:  Angeliki Chroni; Serapion Pyrpassopoulos; Angelos Thanassoulas; George Nounesis; Vassilis I Zannis; Efstratios Stratikos
Journal:  Biochemistry       Date:  2008-08-09       Impact factor: 3.162

4.  Role of the hydrophobic and charged residues in the 218-226 region of apoA-I in the biogenesis of HDL.

Authors:  Panagiotis Fotakis; Andreas K Kateifides; Christina Gkolfinopoulou; Dimitra Georgiadou; Melissa Beck; Katharina Gründler; Angeliki Chroni; Efstratios Stratikos; Dimitris Kardassis; Vassilis I Zannis
Journal:  J Lipid Res       Date:  2013-08-29       Impact factor: 5.922

5.  Molecular mechanisms responsible for the differential effects of apoE3 and apoE4 on plasma lipoprotein-cholesterol levels.

Authors:  Hui Li; Padmaja Dhanasekaran; Eric T Alexander; Daniel J Rader; Michael C Phillips; Sissel Lund-Katz
Journal:  Arterioscler Thromb Vasc Biol       Date:  2013-02-14       Impact factor: 8.311

Review 6.  Role of apoA-I, ABCA1, LCAT, and SR-BI in the biogenesis of HDL.

Authors:  Vassilis I Zannis; Angeliki Chroni; Monty Krieger
Journal:  J Mol Med (Berl)       Date:  2006-02-25       Impact factor: 4.599

7.  apoE3[K146N/R147W] acts as a dominant negative apoE form that prevents remnant clearance and inhibits the biogenesis of HDL.

Authors:  Panagiotis Fotakis; Alexander Vezeridis; Ioannis Dafnis; Angeliki Chroni; Dimitris Kardassis; Vassilis I Zannis
Journal:  J Lipid Res       Date:  2014-04-28       Impact factor: 5.922

8.  Allele-dependent thermodynamic and structural perturbations in ApoE variants associated with the correction of dyslipidemia and formation of spherical ApoE-containing HDL particles.

Authors:  Dimitra Georgiadou; Angeliki Chroni; Konstantinos Drosatos; Kyriakos E Kypreos; Vassilis I Zannis; Efstratios Stratikos
Journal:  Atherosclerosis       Date:  2012-11-23       Impact factor: 5.162

9.  Cholesterol: from feeding to gene regulation.

Authors:  C Martini; V Pallottini
Journal:  Genes Nutr       Date:  2007-09-27       Impact factor: 5.523

Review 10.  Apolipoprotein D in lipid metabolism and its functional implication in atherosclerosis and aging.

Authors:  German Perdomo; H Henry Dong
Journal:  Aging (Albany NY)       Date:  2009-01       Impact factor: 5.682

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.